Clinical Study of GKT in Diabetes Related Dementia

• Status: Not yet recruiting
• Trial end date: 2025-12-31
• Target enrollment: 0
• Participant gender: All

Summary

In 2013, Fukasawa et al. proposed a new clinical dementia subgroup based on brain imaging, called "diabetes related dementia (DrD)". DrD, unlike Alzheimer's disease and vascular dementia, is considered a "controllable" or "modifiable" form of dementia. However, there is currently a lack of corresponding treatment measures. Ginkgo biloba ketone ester tablets are extracts of Ginkgo biloba leaves. Previous studies have shown that they can increase cerebral blood flow, reduce cerebrovascular resistance, improve cerebral circulation, and are beneficial for the treatment of cognitive impairment. This project intends to explore the role of ginkgo ketoester tablets in diabetes related dementia through a multicenter randomized double-blind controlled clinical study.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai 10th People's Hospital

Criteria

Inclusion Criteria:

1. Type 2 diabetes cognitive impairment patients aged 60 years or above;

2. Able to cooperate in completing cognitive function testing;

3. Patients who can swallow pills

Exclusion Criteria:

1. Type 1 diabetes;

2. Acute cerebral infarction and myocardial infarction within 3 months;

3. Severe liver and kidney dysfunction;

4. Late stage malignant tumors;

5. Thyroid dysfunction；

6. Brain injury and cerebral hemorrhage within 3 months；

7. Folic acid and/or vitamin B12 deficiency